Enovis Reports Q3 Sales of $559 Million, Raises 2026 Guidance
Enovis reported 5% organic sales growth and adjusted EPS of $0.88, above the FactSet consensus estimate of $0.77. It raised its full-year adjusted EPS outlook to $3.58-$3.79 and adjusted EBITDA outlook to $428-$438 million, and authorized $200 million in share repurchases, replacing its previous $100 million program.
Enovis Corporation announced its third-quarter 2026 financial results, reporting net sales of $559 million, representing 5% organic growth. The company achieved an adjusted net earnings per diluted share of $0.88, surpassing the FactSet consensus estimate of $0.77. Management raised its full-year adjusted earnings per share guidance to a range of $3.58-$3.79 and increased its adjusted EBITDA outlook to $428-$438 million. Additionally, the Board of Directors approved a new $200 million share repurchase authorization, replacing the previous $100 million program.
The company attributed its performance to continued execution in its Recon and Prevention & Recovery segments and momentum from new product introductions.